Curiox Biosystems Terminates 2.72 Billion Won Equipment Supply Contract

• Curiox Biosystems terminated a KRW 2.72 billion HT and Buffer Exchanger equipment contract on Oct. 29, 2026.
• The canceled contract represented 37.6% of 2022 revenue of KRW 7.24 billion.
• The counterparty was wholly owned subsidiary Curiox Biosystems China, which placed the order following an order from Hunan Deshengyuan Biotechnology.
• Hunan Deshengyuan Biotechnology notified the group that it could not fulfill the contract.
• The contract originally ran from Nov. 1, 2023, through Oct. 31, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Curiox Biosystems Co., Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261029900835), on October 29, 2026, and is solely responsible for the information contained therein.